Study of GB261 for systemic sclerosis
Part of Skin clinical trials.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years
- Diagnosed with systemic sclerosis (specifically the diffuse cutaneous type) for no more than 7 years
- Moderate to severe skin thickening (mRSS score of 15 or higher)
- Not responded well enough to standard treatments
- No other major uncontrolled medical conditions or recent cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests an experimental oral tablet (TollB-001) for people with active diffuse systemic sclerosis, a type of scleroderma that causes skin thickening and internal organ damage. The goal is to see if the drug can help control the disease and improve symptoms.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.